Korean Red Ginseng Shows Promise in Treating Long COVID Symptoms, Clinical Trial Reveals

What Is the Promise of Korean Red Ginseng in Long COVID?

Korean Red Ginseng extract G1899 has demonstrated significant efficacy in reducing anxiety and fatigue symptoms associated with long COVID while improving immune balance in patients recovering from COVID-19 infection, according to a new randomized clinical trial from South Korea. The 12-week study showed that G1899 helped maintain regulatory T cell populations and enhanced CD4/CD8 ratios, suggesting it may attenuate chronic inflammation that contributes to persistent post-COVID symptoms.

The placebo-controlled trial, conducted at Yongin Severance Hospital and registered under Clinical Research Information Service (KCT 20250116-003), enrolled 220 participants within seven days of laboratory-confirmed COVID-19 diagnosis between April 2022 and March 2023. Participants were randomized to receive either G1899 (2g daily) or placebo for 12 weeks, with 108 participants in each group completing the full study protocol. The G1899 intervention contained multiple ginsenosides, including Rb1 (8.03 mg/g), Rb2 (2.80 mg/g), and Rg3 (2.50 mg/g), which are believed to contribute to its immunomodulatory effects. Researchers assessed participants using standardized questionnaires for anxiety (GAD-7) and chronic fatigue syndrome associated with COVID-19, while also conducting comprehensive blood panels and flow cytometry analyses to evaluate immune responses at baseline, 3 weeks, and 12 weeks.

Do the Trial Results Demonstrate Immune Enhancement and Symptom Relief?

The findings revealed gender-specific responses to G1899 treatment. Women in the G1899 group showed significantly greater reductions in anxiety scores compared to the placebo group (p=0.018), with GAD-7 scores decreasing by 1.71 points versus 0.31 points in the placebo group. Similarly, chronic fatigue syndrome symptoms decreased more substantially in women receiving G1899 compared to placebo (p=0.015). While men also experienced improvements in anxiety and fatigue symptoms with G1899, the differences compared to placebo did not reach statistical significance. These gender-specific responses highlight the importance of considering sex as a biological variable in therapeutic interventions for long COVID. Notably, the G1899 group also showed a significant increase in CD4+ T cell percentage from 48.87% at baseline to 56.72% at 12 weeks (p=0.0233) and an improved CD4/CD8 ratio from 1.71 to 2.31 (p=0.0029), whereas no significant changes were observed in the placebo group. The regulatory T cell population remained stable in the G1899 group but significantly decreased in the placebo group (p=0.0005), suggesting that G1899 helps maintain immune regulatory mechanisms during COVID-19 recovery.

Another interesting finding was that blood cortisol levels increased less in the G1899 group compared to placebo (1.21 vs. 2.75, p=0.030), potentially indicating reduced physiological stress. However, anti-SARS-CoV-2 spike antibody levels increased similarly in both groups, suggesting that G1899's benefits may be primarily mediated through cellular rather than humoral immunity. Importantly, no adverse events were reported with G1899 administration, supporting its favorable safety profile. The study also revealed that both groups experienced similar reductions in inflammatory markers (CRP, WBC, neutrophils) over the 12-week period, with no significant between-group differences, indicating that the benefits of G1899 likely extend beyond simple anti-inflammatory effects to more complex immunomodulatory mechanisms. These findings add to the growing body of evidence supporting the potential therapeutic role of Korean Red Ginseng in post-viral syndromes.

The researchers used a comprehensive approach to assess long COVID symptoms through validated questionnaires. The Chronic Fatigue Syndrome associated with COVID-19 (CFS-COVID19) questionnaire evaluated eight key symptoms: myalgia, headache, odynophagia, non-restorative sleep, post-exertional malaise, painful cervical/axillary adenopathy, concentration/memory disorders, and polyarthralgia without inflammatory signs. This detailed symptom assessment allowed for precise tracking of the multifaceted manifestations of long COVID. Additionally, the study employed sophisticated immunological analyses, including flow cytometry to characterize T cell populations and ECLIA tests to measure SARS-CoV-2 antibodies against both nucleocapsid and spike proteins.

What Are the Limitations and Future Directions of the Study?

While promising, the study has several limitations that warrant consideration. The 12-week follow-up period may be insufficient to evaluate the long-term trajectory of long COVID, which can persist for months or years. Additionally, the timing of antibody measurements varied due to quarantine regulations and testing intervals, making it challenging to fully assess G1899's effect on antibody dynamics. The researchers also acknowledged that certain blood tests that could affect fatigue, such as thyroid function tests, were not performed, although stress hormones like cortisol were measured. Despite these limitations, this study provides valuable insights into the potential therapeutic application of G1899 in managing long COVID symptoms and improving immune balance. The results suggest that Korean Red Ginseng extract could serve as a safe and effective adjunct therapy for individuals experiencing persistent symptoms following COVID-19 infection.

The study authors concluded that G1899 demonstrates significant effects in alleviating long COVID symptoms, improving immune balance, and stabilizing regulatory T cell populations in patients with COVID-19. They recommended that future studies focus on optimizing dosage regimens, investigating long-term effects beyond 12 weeks, and further elucidating G1899's mechanisms of action to maximize its therapeutic potential. The findings have important implications for healthcare providers seeking additional tools to address the growing burden of long COVID, which affects a substantial proportion of COVID-19 survivors and currently has limited standardized treatment options.

How Does This Research Impact the Industry Landscape?

Industry Context: This study aligns with the growing interest in natural compounds with immunomodulatory properties as potential interventions for long COVID, a condition that continues to challenge healthcare systems globally. As pharmaceutical companies race to develop targeted therapies for post-viral syndromes, this research highlights the potential of evidence-based natural products to address the complex immunological dysregulation underlying long COVID. The findings come at a time when the nutraceutical and traditional medicine sectors are experiencing increased scrutiny and demand for rigorous clinical evidence, positioning Korean Red Ginseng extract as a scientifically-supported option in the expanding market for long COVID interventions.

Summary

A 12-week randomized clinical trial involving 220 COVID-19 patients has demonstrated the effectiveness of Korean Red Ginseng extract G1899 in treating long COVID symptoms. The study showed significant reductions in anxiety and fatigue, particularly among female participants, with G1899 group showing improved CD4+ T cell percentages and CD4/CD8 ratios. The treatment helped maintain regulatory T cell populations and showed lower cortisol level increases compared to placebo, indicating reduced physiological stress. While both groups showed similar antibody responses, G1899 demonstrated a favorable safety profile with no reported adverse events. The research suggests that Korean Red Ginseng extract could serve as a safe and effective complementary therapy for long COVID management, though longer-term studies are needed to fully evaluate its potential.